Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (opens new window)

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Source‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indexed‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718 (opens new window)

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (opens new window)

Banan M.

Source‎: Ann Hematol 2013;92(3):289-99.

Indexed‎: PubMed 23318979

DOI‎: 10.1007/s00277-012-1671-3

https://www.ncbi.nlm.nih.gov/pubmed/23318979 (opens new window)

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (opens new window)

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Source‎: Transfusion 2007;47(10):1830-6.

Indexed‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608 (opens new window)

Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (opens new window)

Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rodgers GP.

Source‎: Blood 1996;87(3):887-92.

Indexed‎: PubMed 8562958

https://www.ncbi.nlm.nih.gov/pubmed/8562958 (opens new window)

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (opens new window)

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Source‎: Iran J Blood Cancer 2009;1(4):147-50.

Indexed‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (opens new window)

Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (opens new window)

Karimi M, Cohan N, Pishdad P.

Source‎: Hematology 2015;20(1):53-7.

Indexed‎: PubMed 24717020

DOI‎: 10.1179/1607845414Y.0000000168

https://www.ncbi.nlm.nih.gov/pubmed/24717020 (opens new window)

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (opens new window)

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Source‎: Int J Hematol 2012;95(1):51-6.

Indexed‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324 (opens new window)

Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (opens new window)

Kosaryan M, Karami H, Zafari M, Yaghobi N.

Source‎: Hemoglobin 2014;38(2):115-8.

Indexed‎: PubMed 24471558

DOI‎: 10.3109/03630269.2013.869229

https://www.ncbi.nlm.nih.gov/pubmed/24471558 (opens new window)

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (opens new window)

Musallam KM, Taher AT, Cappellini MD, Sankaran VG.

Source‎: Blood 2013;121(12):2199-212.

Indexed‎: PubMed 23315167

DOI‎: 10.1182/blood-2012-10-408021

https://www.ncbi.nlm.nih.gov/pubmed/23315167 (opens new window)

A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (opens new window)

Yasara N, Wickramarathne N, Mettananda C, Silva I, Hameed N, Attanayaka K, Rodrigo R, Wickramasinghe N, Perera L, Manamperi A, Premawardhena A, Mettananda S

Source‎: Sci Rep. 2022;12(1):2752.

Indexed‎: PubMed 35177777

DOI‎: 10.1038/s41598-022-06774-8

https://pubmed.ncbi.nlm.nih.gov/35177777/ (opens new window)

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (opens new window)

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Source‎: Haematologica 2004;89(10):1172-8.

Indexed‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200 (opens new window)

Hydroxyurea therapy in 49 patients with major beta-thalassemia. (opens new window)

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Source‎: Arch Iran Med 2009;12(3):295-7.

Indexed‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608 (opens new window)

Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (opens new window)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Source‎: Eur J Haematol 1996;56(5):326-8.

Indexed‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (opens new window)

Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (opens new window)

Breymann C, Fibach E, Visca E, Huettner C, Huch A, Huch R.

Source‎: J Matern Fetal Med 1999;8(1):1-7.

Indexed‎: PubMed 10052837

DOI‎: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O

https://www.ncbi.nlm.nih.gov/pubmed/10052837 (opens new window)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (opens new window)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Source‎: Acta Haematol 2004;111(4):189-95.

Indexed‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (opens new window)

Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (opens new window)

Makis AC, Chaliasos N, Hatzimichael EC, Bourantas KL.

Source‎: Ann Hematol 2001;80(8):492-5.

Indexed‎: PubMed 11563599

https://www.ncbi.nlm.nih.gov/pubmed/11563599 (opens new window)

Fetal globin induction--can it cure beta thalassemia? (opens new window)

Perrine SP.

Source‎: Hematology Am Soc Hematol Educ Program 2005:38-44.

Indexed‎: PubMed 16304357

DOI‎: 10.1182/asheducation-2005.1.38

https://www.ncbi.nlm.nih.gov/pubmed/16304357 (opens new window)